On Tuesday, Colony Capital Inc (NYSE:CLNY)’s shares inclined 1.04% to $23.34.
Colony Capital Inc., a public (CLNY), international investment firm, declared recently that Christophe G. de Taurines has joined the firm as Managing Director—European Investor Relations.
Based in Colony’s London office, Mr. de Taurines, 50, will principally be responsible for expanding Colony’s investor relationships in Europe, while also assisting with the firm’s European strategy and operations.
Colony Capital, Inc., a commercial real estate and investment administration company, acquires, originates, and manages a portfolio of real estate-related debt and equity investments in North America and Europe. It operates through four segments: Real Estate Debt Investments, Light Industrial Portfolio, Single-Family Residential Rentals, and Other Real Estate Equity Investments.
Credit Suisse Group AG (ADR) (NYSE:CS)’s shares gained 1.69% to $29.48.
Credit Suisse Group AG (ADR) (CS) driven by supply fundamentals and macroeconomic factors, according to Credit Suisse Asset Management.
The Bloomberg Commodity Index Total Return performance was negative for the month, with 15 out of 22 Index constituents trading lower.
Credit Suisse Asset Administration observed the following:
- Industrial Metals was the worst performing sector, down 7.70%, as a continued weak economic growth outlook for China weighed on demand expectations.
- Agriculture declined 3.50%, led lower by softs, as a weaker Brazilian Real incentivized exports of sugar, coffee and soybeans. In addition, heavy rainfall improved the coffee harvest outlook in Brazil and Colombia, increasing supply expectations.
- Energy finished the month 2.13% lower, led by Natural Gas. Inventories rose more than predictable towards the end of the month, and forecasts for moderate weather across the U.S. reduced cooling demand expectations.
- Livestock gained the most, up 2.34%. In addition to Lean Hogs, Live Cattle also ended the month higher following raised wholesale beef demand. Furthermore, good pasture conditions incentivized producers to hold back cattle, shrinking near term supplies.
Credit Suisse Group AG, together with its auxiliaries, provides various financial services to private, corporate, institutional, government clients, and high-net-worth individuals, in addition to affluent and retail clients worldwide. The company operates through two segments, Private Banking & Wealth Administration and Investment Banking. The Private Banking & Wealth Administration segment offers a range of advice and financial solutions, counting structured advisory to high-net-worth clients; banking products, such as lending, cash and liquidity administration, trade finance, ship and aviation finance, corporate finance, investment solutions, custody, and asset and liability administration; and investment solutions and services to pension funds, governments, foundations and endowments, corporations, and individuals.
At the end of Tuesday’s trade, Alder Biopharmaceuticals Inc (NASDAQ:ALDR)‘s shares surged 0.68% to $48.90.
Alder BioPharmaceuticals, Inc. (ALDR), a clinical-stage biopharmaceutical company, declared recently that the underwriters of its formerly declared public offering of common stock have exercised in full their option to purchase an additional 674,157 shares of common stock. The closing of the sale of all shares occurred recently. Gross proceeds from the offering of an aggregate of 5,168,539 shares at a public offering price of $44.50 per share, before underwriting discounts and commissions and offering expenses, were about $230 million.
Credit Suisse, Leerink Partners and Wells Fargo Securities acted as joint book-running managers for the offering. Bernstein acted as co-manager for the offering.
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia. It is developing monoclonal antibodies comprising ALD403, which has accomplished Phase Ib proof-of-concept trials to target calcitonin gene-related peptide for the prevention of migraine; Clazakizumab that has accomplished Phase IIb clinical trials that inhibits the pro-inflammatory cytokine interleukin-6 in the treatment of rheumatoid arthritis and psoriatic arthritis; and ALD1613, which is in preclinical stage of development for the treatment of Cushing’s disease.
Peregrine Pharmaceuticals (NASDAQ:PPHM), ended its Tuesday’s trading session with 2.27% gain, and closed at $1.35.
Peregrine Pharmaceuticals, Inc. (PPHM) a biopharmaceutical company focused on developing novel investigational products that assist harness the body’s own immune system to fight cancer, recently declared that it will report financial results for the fourth quarter and fiscal year (FY) 2015 ended April 30, 2015 on July 14, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine’s senior administration will talk about financial results for the fourth quarter ended April 30, 2015 of FY 2015 and will review recent progress of its clinical development programs.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer together with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
